Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Melan-A VLP Vaccine in Advanced Melanoma
NCT00306514Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CYT004-MelQbG10 in melanoma, sponsored by Cytos Biotechnology AG. Primary endpoints: Safety and Tolerability and Specific Cellular Immune Response. Status: completed.
02
Drugs
CYT004-MelQbG10
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00306514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306514.